Biopharma, a blood products maker, plans to bring tetanus immune globulin (TIG) to the market by the end of 2019, Biopharma Group President Kostiantyn Yefymenko has said in an interview with Interfax-Ukraine. “Taking into account the country’s needs, we are working on the specific tetanus immune globulin. We hope that we would be able to bring it to the market by late 2019,” he said.
Biopharma is one of the ten largest Ukrainian producers of medicines. It produces more than 20 immunobiological preparations from donor blood, preparations obtained by recombinant DNA technology and probiotics.
